Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd. is nearing the completion of its Phase II clinical trial for RECCE 327 Topical Gel, a synthetic anti-infective targeting acute bacterial skin and skin structure infections, with promising results. All 20 dosed patients out of 30 have shown either a complete cure or notable improvement, and no serious adverse events have been reported. This progress positions the company to address a market projected to reach USD 26 billion by 2032.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
